Roche's pharma sales up by 7%
This article was originally published in Scrip
Executive Summary
Roche said strong demand for its HER2 breast-cancer franchise, plus Avastin and Actemra/RoActemra, led to a 7% increase in pharmaceuticals sales for the first nine months of 2013. US sales grew by 12%.